Turning theory into practice: The development of modern transdermal drug delivery systems and future trends

Skin Pharmacology and Physiology

Volumn 26, Issue 4-6, 2013, Pages 331-342

  Perumal, O ^a   Murthy, S N ^b   Kalia, Y N ^c  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Drug delivery; Heat activated delivery; Iontophoresis; Skin; Transdermal patch

Indexed keywords

BUPRENORPHINE; CLONIDINE; ESTRADIOL; FENTANYL; GLYCERYL TRINITRATE; GRANISETRON; LEVONORGESTREL; METHYLPHENIDATE; NICOTINE; NORELGESTROMIN; NORETHISTERONE ACETATE; OXYBUTYNIN; RIVASTIGMINE; ROTIGOTINE; SCOPOLAMINE; SELEGILINE; TESTOSTERONE;

ANGINA PECTORIS; ARTICLE; ATTENTION DEFICIT DISORDER; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC PAIN; DEMENTIA; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; HEAT ACTIVATED DRUG DELIVERY SYSTEM; HUMAN; HYPERTENSION; KINETICS; MACROMOLECULE; MATHEMATICAL MODEL; MENOPAUSAL SYNDROME; MICRONEEDLE; MOTION SICKNESS; OVERACTIVE BLADDER; PARKINSON DISEASE; PRIORITY JOURNAL; SKIN; SKIN ABSORPTION; TEMPERATURE; THEORY; TRANSDERMAL DRUG DELIVERY SYSTEM;

ADMINISTRATION, CUTANEOUS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MACROMOLECULAR SUBSTANCES; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; SKIN; SKIN ABSORPTION; TECHNOLOGY, PHARMACEUTICAL;

EID: 84881416421     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000351815     Document Type: Article

References (54)

1. Cleary GW: Microneedles for drug delivery. Pharm Res 2011; 28: 1-6.
2. Rein H: Experimental electroendosmotic studies on living human skin. Z Biol 1924; 81: 124.
3. Blank IH: Penetration of low-molecularweight alcohols into skin. I. Effect of concentration of alcohol and type of vehicle. J Invest Dermatol 1965; 43: 415-420.
4. Scheuplein RJ: Mechanism of percutaneous adsorption. I. Routes of penetration and the influence of solubility. J Invest Dermatol 1965; 45: 334-345.
5. Scheuplein RJ, Blank IH: Permeability of the skin. Physiol Rev 1971; 51: 702-747.
6. Rothman S: The principles of percutaneous absorption. J Lab Clin Med 1943; 28: 1305-1321.
7. Hadgraft JW, Somers GF: Percutaneous absorption. J Pharm Pharmacol 1956; 8: 625-634.
8. Higuchi T: Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem 1960; 11: 85-97.
9. Michaels AS, Chandrasekaran SK, Shaw JE: Drug permeation through human skin: theory and in vitro experimental measurement. AIChE J 1975; 21: 985-996.
10. Cleary GW: Transdermal delivery systems: a medical rationale; in Shah VP, Maibach HI (eds): Topical Drug Bioavailability. Bioequivalence and Penetration. New York, Plenum Press, 1993, pp 17-68.
11. Blank IH, Scheuplein RJ: The epidermal barrier; in Rook AJ, Champion RH (eds): Progress in the Biological Sciences in Relation to Dermatology. Cambridge, Cambridge University Press, 1964, vol 2, pp 245-261.
12. Kandavalli S, Nair V, Panchagnula R: Polymers in transdermal drug delivery systems. Pharm Technol 2002;May:62-80.
13. Cleary GW: Transdermal controlled release systems; in Langer RS, Wise DL (eds): Medical Applications of Controlled Release. Boca Raton, CRC Press, 1984, vol 1, p 203.
14. Feldmann RJ, Maibach HI: Regional variation in percutaneous penetration of 14 C-cortisol in man. J Invest Dermatol 1967; 48: 181-183.
15. Prausnitz MR, Mitragotri S, Langer R: Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004; 3: 115-124.
16. Hill LA: Transdermal pharmaceuticals: unique aspects of clinical development. Transdermal 2009;Nov:14-17.
17. Levin-Epstein M: A new way to deliver psychiatric meds. Behav Healthcare 2006; 26: 22-23.
18. Margetts L, Sawyer R: Transdermal drug delivery: principles and opioid therapy. Cont Edu Anaesth Crit Care Pain 2007; 7: 171-177.
19. Tan HS, Pfister WR: Pressure-sensitive adhesives for transdermal drug delivery systems. Pharm Sci Technol Today 1999; 2: 60-69.
20. Wolff HM: Optimal process design for the manufacture of transdermal drug delivery systems. Pharm Sci Technol Today 2000; 3: 173-181.
21. Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL: Challenges and opportunities in dermal/transdermal delivery. Ther Deliv 2010; 1: 109-131.
22. Thomas BJ, Finnin BC: The transdermal revolution. Drug Discov Today 2004; 9: 697-703.
23. Pellett MA, Raghavan SA, Hadgraft J, Davis AF: The application of supersaturated systems to percutaneous drug delivery; in Guy RH, Hadgraft J (eds): Transdermal Drug Delivery. New York, Dekker, 2003, vol 23, pp 305-326.
24. Blank IH, Scheuplein RJ, Macfarlane DJ: Mechanism of percutaneous absorption. III. The effect of temperature on the transport of non-electrolytes across the skin. J Invest Dermatol 1967; 49: 582-589.
25. Lawson EE, Anigbogu ANC, Williams AC, Barry BW, Edwards HGM: Thermally induced molecular disorder in human stratum corneum lipids compared with a model phospholipid system; FT-Raman spectroscopy. Spectrochim Acta Part 1998; 54: 543-558.
26. Bouwstra JA, Gooris GS, Weerheim A, Kempenaar J, Ponec M: Characterization of stratum corneum structure in reconstructed epidermis by X-ray diffraction. J Lipid Res 1995; 36: 496-504.
27. Xiao K, Dong CF, Li SG, Wang FM: Corrosion products and formation mechanism during initial stages of atmospheric corrosion of carbon steel. J Iron Steel Res Int 2008; 15: 42-48.
28. Majzlan J, Grevel KD, Navrotsky A: Thermodynamics of Fe oxides. II. Enthalpies of formation and relative stability of goethite (α-FeOOH), lepidocrocite (γ-FeOOH), and maghemite (γ-Fe 2 O 3 ). Am Mineral 2003; 88: 855-859.
29. Friedman PM, Mafong EA, Friedman ES, Geronemus RG: Topical anesthetics update: EMLA and beyond. Dermatol Surg 2001; 27: 1019-1026.
30. Sawyer J, Febbaro S, Masud S, Ashburn MA, Campbell JC: Heated lidocaine/tetracaine patch (Synera, Rapydan) compared with lidocaine/ priklocaine cream (EMLA) for topical anaesthesia before vascular access. Br J Anesth 2009; 102: 210-215.
31. Kalia YN, Naik A, Garrison J, Guy RH: Iontophoretic drug delivery. Adv Drug Deliv Rev 2004; 56: 619-658.
32. Subramony JA, Sharma A, Phipps JB: Microprocessor controlled transdermal drug delivery. Int J Pharm 2006; 317: 1-6.
33. Pikal MJ: Transport mechanisms in iontophoresis. 1. A theoretical model for the effect of electroosmotic flow on flux enhancement in transdermal iontophoresis. Pharm Res 1990; 7: 118-126.
34. Zempsky WT, Sullivan J, Paulson DM, Hoath SB: Evaluation of a low-dose lidocaine iontophoresis system for topical anesthesia in adults and children: a randomized, controlled trial. Clin Ther 2004; 26: 1110-1119.
35. Gupta SK, Bernstein KJ, Noorduin H, Van Peer A, Sathyan G, Haak R: Fentanyl delivery from an electrotransport system: delivery is a function of total current, not duration of current. J Clin Pharmacol 1998; 38: 951-958.
36. Chelly JE, Grass J, Houseman TW, Minkowtiz H, Pue A: The safety and efficacy of a fenta nyl patient-controlled transdermal system for acute postoperative analgesia: a multicenter, placebo-controlled trial. Anesth Analg 2004; 98: 427-433.
37. Viscusi ER, Reynolds L, Chung F, Atkinson LE, Khanna S: Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. JAMA 2004; 291: 1333-1341.
38. Hartrick CT, Bourne MH, Gargiulo K, Damaraju CV, Vallow S, Hewitt DJ: Fentanyl iontophoretic transdermal system for acute-pain management after orthopedic surgery: a comparative study with morphine intravenous patient-controlled analgesia. Reg Anesth Pain Med 2006; 31: 546-554.
39. Ahmad S, Hewitt DJ, Damaraju CV: Fentanyl HCl iontophoretic transdermal system versus intravenous morphine pump after gynecologic surgery. Arch Gynecol Obstet 2007; 276: 251-258.
40. Siegel SJ, O'Neill C, Dubé LM, Kaldeway P, Morris R, Jackson D, Sebree T: A unique iontophoretic patch for optimal delivery of sumatriptan. Pharm Res 2007; 24: 1919-1926.
41. Patel SR, Zhong H, Sharma A, Kalia YN: In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. Eur J Pharm Biopharm 2007; 66: 296-301.
42. Patel SR, Zhong H, Sharma A, Kalia YN: Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo. Eur J Pharm Biopharm 2009; 72: 304-309.
43. Schulman EA: Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea. Headache 2012; 52: 204-212.
44. Smith TR, Goldstein J, Singer R, Pugach N, Silberstein S, Pierce MW: Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache 2012; 52: 612-624.
45. Cazares-Delgadillo J, Naik A, Ganem-Rondero A, Quintanar-Guerrero D, Kalia YN: Transdermal delivery of cytochrome C-a 12.4 kDa protein-across intact skin by constant-current iontophoresis. Pharm Res 2007; 24: 1360-1368.
46. Dubey S, Kalia YN: Non-invasive iontophoretic delivery of enzymatically active ribonuclease A (13.6 kDa) across intact porcine and human skins. J Control Release 2010; 145: 203-209.
47. Dubey S, Kalia YN: Electrically assisted delivery of an anionic protein across intact skin: cathodal iontophoresis of biologically active ribonuclease T1. J Control Release 2011; 152: 356-362.
48. Dubey S, Perozzo R, Scapozza L, Kalia YN: Noninvasive transdermal iontophoretic delivery of biologically active human basic fibroblast growth factor. Mol Pharm 2011; 8: 1322-1331.
49. Ameri M, Daddona PE, Maa Y-F: Parathyroid hormone PTH (1-34) formulation that enables uniform coating on a novel transdermal microprojection delivery system. Pharm Res 2009; 27: 303-313.
50. Cosman F, Lane NE, Bolognese MA, Zanchetta JR, Garcia-Hernandez PA, Sees K, Matriano JA, Gaumer K, Daddona PE: Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010; 95: 151-158.
51. Daddona PE, Matriano JA, Mandema J, Maa Y-F: Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm Res 2011; 28: 159-165.
52. Rao G, Glikfeld P, Guy RH: Reverse iontophoresis: development of a noninvasive approach for glucose monitoring. Pharm Res 1999; 10: 1751-1755.
53. Erickson D: Skinside out. Drug delivery in reverse could be a diabetic's boon. Sci Am 1991; 265: 128-130.
54. Ansaldi F, de Florentiis D, Durando P, Icardi G: Fluzone ® intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev Vaccines 2012; 11: 17-25.